NSE: GLENMARK - Glenmark Pharmaceuticals Limited

Yield per half year: +70.99%
Sector: Healthcare

Company Analysis Glenmark Pharmaceuticals Limited

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The stock's return over the last year (128.51%) is higher than the sector average (-41.78%).
  • Current debt level 8.57% is below 100% and has decreased over 5 years from 35.63%.

Disadvantages

  • Price (1649.8 β‚Ή) is higher than fair price (666.45 β‚Ή)
  • Dividends (0.1443%) are below the sector average (9.59%).
  • The company's current efficiency (ROE=-19.13%) is lower than the sector average (ROE=7.22%)

Similar companies

IndusInd Bank Limited

Apollo Hospitals Enterprise Limited

Divi's Laboratories Limited

Torrent Pharmaceuticals Limited

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Glenmark Pharmaceuticals Limited Healthcare Index
7 days 8.1% 4.7% -1.6%
90 days 28.7% 12.8% -3.3%
1 year 128.5% -41.8% 12.2%

GLENMARK vs Sector: Glenmark Pharmaceuticals Limited has outperformed the "Healthcare" sector by 170.29% over the past year.

GLENMARK vs Market: Glenmark Pharmaceuticals Limited has outperformed the market by 116.34% over the past year.

Stable price: GLENMARK is not significantly more volatile than the rest of the market on "National Stock Exchange Of India" over the last 3 months, with typical variations of +/- 5% per week.

Long period: GLENMARK with weekly volatility of 2.47% over the past year.

3. Summary of the report

3.1. General

P/E: 40.73
P/S: 2.27

3.2. Revenue

EPS -53.22
ROE -19.13%
ROA -10.46%
ROIC 2.94%
Ebitda margin 10.12%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (1649.8 β‚Ή) is higher than the fair price (666.45 β‚Ή).

Price is higher than fair: The current price (1649.8 β‚Ή) is 59.6% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (40.73) is lower than that of the sector as a whole (59.31).

P/E vs Market: The company's P/E (40.73) is lower than that of the market as a whole (53.81).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (3.42) is lower than that of the sector as a whole (6.53).

P/BV vs Market: The company's P/BV (3.42) is lower than that of the market as a whole (5.55).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (2.27) is lower than that of the sector as a whole (8.62).

P/S vs Market: The company's P/S indicator (2.27) is lower than that of the market as a whole (16.9).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (22.09) is lower than that of the sector as a whole (141.72).

EV/Ebitda vs Market: The company's EV/Ebitda (22.09) is lower than that of the market as a whole (36.92).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Negative and has fallen by -53.68% over the last 5 years.

Earnings Slowdown: The last year's return (-605.2%) is below the 5-year average return (-53.68%).

Profitability vs Sector: The return for the last year (-605.2%) is lower than the return for the sector (38.16%).

5.4. ROE

ROE vs Sector: The company's ROE (-19.13%) is lower than that of the sector as a whole (7.22%).

ROE vs Market: The company's ROE (-19.13%) is lower than that of the market as a whole (12.05%).

5.5. ROA

ROA vs Sector: The company's ROA (-10.46%) is lower than that of the sector as a whole (6.7%).

ROA vs Market: The company's ROA (-10.46%) is lower than that of the market as a whole (7.41%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (2.94%) is lower than that of the sector as a whole (15.91%).

ROIC vs Market: The company's ROIC (2.94%) is lower than that of the market as a whole (15.54%).

6. Finance

6.1. Assets and debt

Debt level: (8.57%) is quite low in relation to assets.

Debt reduction: over 5 years, the debt has decreased from 35.63% to 8.57%.

Excess of debt: The debt is not covered by net income, percentage -81.97%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0.1443% is below the average for the sector '9.59%.

7.2. Stability and increase in payments

Dividend stability: The company's dividend yield 0.1443% has been steadily paid over the past 7 years, DSI=1.

Weak dividend growth: The company's dividend yield 0.1443% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (39.61%) are at a comfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Glenmark Pharmaceuticals Limited

9.3. Comments